Nuvaxovid NVX-CoV2373 vaccine safety profile: real-world data evidence after 100,000 doses, Australia, 2022 to 2023

Introduction Nuvaxovid became available in Australia from February 2022, a year after the first COVID-19 vaccines. This protein-based vaccine was an alternative for people who had had an adverse event to and/or were hesitant to receive an mRNA or adenovirus-based COVID-19 vaccine. Although safety fr...

Celý popis

Podrobná bibliografie

Hlavní autor:	Jim P Buttery
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	European Centre for Disease Prevention and Control 2024-12-01
Edice:	Eurosurveillance
Témata:	surveillance adverse events Vaccine safety immunisation, COVID, Nuvaxovid, myocarditis, pericarditis
On-line přístup:	https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2024.29.50.2400164
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!